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Abstract: Seizures are not an uncommon occurrence in older adults, and the incidence of status 
epilepticus is much greater in the elderly than in younger populations. Status epilepticus is a 
neurologic emergency and requires prompt intervention to minimize morbidity and mortality. 
Treatment involves both supportive care as well as initiation of medications to stop all clinical 
and electrographic seizure activity. Benzodiazepines are used as first-line agents, followed by 
antiepileptic drugs when seizures persist. In refractory status epilepticus, urgent neurologic 
consultation is indicated for the titration of anesthetic agents to a level of appropriate background 
suppression on EEG. In light of our aging population, physician awareness and competence 
in the management of status epilepticus is imperative and should be recognized as a growing 
public health concern.
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Status epilepticus
Definition: Traditionally, status epilepticus is defined as continuous or intermitted 
seizure activity of at least 30 minutes in duration. However, continuous seizure 
activity or discrete seizures with incomplete recovery of consciousness lasting 
more than 5 minutes warrants treatment to prevent more prolonged or refractory 
status epilepticus.1 When status epilepticus persists despite treatment with adequate 
doses of at least 2 antiepileptic medications, it is deemed refractory. Whereas 
convulsive status epilepticus refers to seizures characterized by motor activity, 
nonconvulsive status epilepticus may be more difficult to recognize clinically but 
should be suspected when there is prolonged alteration in consciousness in the 
absence of convulsions. Diagnosis requires a high index of suspicion as well as 
EEG confirmation.
Etiology: The incidence of epilepsy in individuals over the age of 65 years is 
estimated to be 134 per 100,000.2 Status epilepticus is 2 to 5 times more common 
in the elderly than in young adults with an incidence of 86 per 100,000 annually in 
those over the age of 60.3 In fact, nearly one-third of older patients with new-onset 
epilepsy initially present in status epilepticus.4 Children often present in status epi-
lepticus as a consequence of febrile illness, whereas the most common identifiable 
cause of seizures and status in the elderly include cerebrovascular disease, degen-
erative disease, neoplasm, infection, and trauma.5 Other potential causes include 
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metabolic derangements, alcohol withdrawal, drug use or 
withdrawal, and toxins. The clinician must be cognizant of 
potential mimickers such as convulsive syncope, asterixis, 
myoclonus, and psychogenic nonepileptic attacks which 
may be mistaken for convulsive seizures. The differential 
diagnosis for nonconvulsive status epilepticus includes 
encephalopathic conditions and degenerative illnesses such 
as Creutzfeldt–Jakob disease which may present with a 
similar altered sensorium.
Economics: In the United States, an estimated 152,000 
cases of status epilepticus occur each year, resulting in 
42,000 deaths and inpatient costs of US$4 billion annual-
ly.3 The morbidity associated with those who survive the 
event incurs significant additional expense that is difficult 
to precisely quantify.
Level of evidence: There are randomized controlled trials 
that provide a high level of evidence for appropriate first-
line agents in the treatment of status epilepticus in adults. 
Drug treatment approaches in refractory status epilepticus 
are based on prospective observational studies, retrospective 
series, case reports, and expert opinions.
Search sources: PubMed, Cochrane Library, and websites 
of the World Health Organization, the International League 
against Epilepsy, and the American Academy of Neurology, 
1983–2010.
Outcomes: Overall, the short-term mortality associated 
with status epilepticus is 22% and is independently related 
not only to seizure duration but also the etiology of the event 
and the age of the patient. In the elderly, status epilepticus 
is associated with a higher mortality rate than in younger 
patients. Mortality for those adults over 60 years of age 
is 38%, and nearly 50% for those over the age of 80.3 The 
short-term mortality risk for status epilepticus exceeding 
60 minutes in duration is 10 times higher than status lasting 
less than 1 hour, which emphasizes the necessity for rapid 
intervention. Refractory status epilepticus occurs in about 
30% of status epilepticus cases and is associated with higher 
morbidity and mortality rates than nonrefractory cases. In 
elderly patients, refractory status epilepticus may lead to 
death in 76% of cases.6
Among the various etiologies of status epilepticus, 
anoxic brain injury is associated with the highest rate of 
mortality, whereas subtherapeutic antiepileptic drug levels 
have the lowest mortality rates.7 Recurrent episodes are 
not an uncommon phenomenon, on average 25% for most 
etiologies.
There is controversy as to whether prolonged seizures 
are associated with long-term cognitive effects and further 
studies are needed to assess neuropsychological outcomes 
after status epilepticus.8 One study examining 10 patients 
with episodes of nonconvulsive status epilepticus of various 
etiologies, lasting between 36 and 72 hours, demonstrated a 
decline in cognitive function and memory in all survivors. 
Only 2 of the 7 survivors had documented neuropsycho-
metric testing before and after the events.9 A prospective 
study of adult epilepsy patients with and without episodes 
of status epilepticus demonstrated no change in IQ test-
ing before and after the incidence of status compared 
with matched controls.10 Due to the presence of frequent 
pre-existing neurologic conditions, lack of baseline neu-
ropsychometric testing, and varying etiologies, duration, 
and treatments of status epilepticus, this remains a difficult 
topic to study.
Consumer summary: Status epilepticus is a neurologic 
emergency that requires prompt intervention. Prolonged 
seizures are not an uncommon phenomenon in the elderly 
and they unfortunately carry a high risk of death and per-
manent neurologic injury. If the seizures persist despite the 
use of antiseizure medications, it may be necessary to use 
sedating medications to induce a coma and calm the brain 
activity. The ultimate prognosis not only depends on patient 
age and seizure duration, but also is determined largely by 
the underlying cause of the seizure.8
The evidence
There have been 6 randomized controlled trials on this   
topic to date. Initial management of status epilepticus in 
adults should be with a benzodiazepine and it is safe to 
begin therapy outside of the hospital. If available, intrave-
nous lorazepam should be used in preference to diazepam 
because of better efficacy and lower risk of seizure recur-
rence. Although intravenous valproic acid has demonstrated 
efficacy and safety in multiple studies, experience at this 
point is too limited to allow recommendation of its use as a 
first-line agent.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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conclusions based on literature review
•	 Initial treatment of status epilepticus should be with 
a benzodiazepine, preferably intravenous lorazepam.
•	 Seizures will persist in approximately one-third of cases and 
lorazepam should be followed by administration of intra-
venous fosphenytoin. Fosphenytoin can be infused more 
quickly and with less risk of side effects than phenytoin.
•	 Other antiepileptic medications such as levetiracetam, 
valproic acid, and lacosamide may prove to be safe and 
efficacious alternatives; however there are no randomized 
controlled trials to support their use as first- or second-line 
agents at this time.
•	 Refractory status epilepticus requires anesthetic levels 
of drugs, thus requiring intubation, mechanical venti-
lation, and often vasopressor support. Phenobarbital, 
pentobarbital, propofol, midazolam, and ketamine can 
all be used as continuous infusions and titrated to the 
desired level of seizure suppression or background 
slowing on EEG. There are no prospective randomized 
trials to demonstrate which drug is most effective, and 
retrospective series suggest that the choice of agent does 
not statistically affect mortality. Medical comorbidities 
of the patient often help to determine which medication 
is most appropriate.
Table 1 Available evidence for the initial pharmacologic management of status epilepticus
Author N Interventions Outcome measures Results Comments
Alldredge  
et al11
205 iv diazepam (5 mg) vs  
iv lorazepam (2 mg) vs  
placebo
Termination of status,  
respiratory or circulatory  
complications
BZDs are safe and effective,  
lorazepam more effective  
than diazepam
class i. Pre-hospital  
treatment of SE in adults
Leppik  
et al12
81 iv lorazepam (4 mg) vs  
iv diazepam (10 mg)  
with repeat dosing  
if needed
Termination of status,  
adverse effects
89% success with lorazepam,  
76% with diazepam, no significant  
difference in adverse effects
class ii.
Treiman  
et al13
518 iv diazepam (0.15 mg/kg)  
+ PHT (18 mg/kg) vs  
lorazepam (0.1 mg/kg) vs  
PHB (15 mg/kg) vs  
PHT (18 mg/kg)
Termination of status within  
20 min of drug infusion and  
no return of seizure activity  
during next 40 min
Lorazepam superior to PHT  
in GcSE. No difference among  
drugs in NcSE.
Class I. No significant  
difference in lorazepam  
vs diazepam + PHT or  
lorazepam vs PHB, but  
lorazepam easier to use
Misra  
et al14
68 iv vPA (30 mg/kg) vs  
iv PHT (18 mg/kg)
clinical seizure cessation  
after infusion and seizure 
freedom at 24 h
vPA was more effective than  
PHT in controlling GcSE, both  
as the first (66% vs 42%) and  
second choice (79% vs 25%)
class iii. Excluded NcSE,   
included children  
and adolescents,  
underpowered
Gilad  
et al15
74 iv vPA (30 mg/kg) vs  
iv PHT (18 mg/kg)
clinical seizure cessation,  
drug tolerability
vPA effective in 87.8% and PHT  
effective in 88%. Side effects  
occurred in 12% of PHT group  
and none in vPA group.
class iii. Underpowered
Agarwal  
et al16
100 After failure of control  
with diazepam, iv vPA  
(20 mg/kg) vs  
iv PHT (20 mg/kg)
Termination of status within  
20 min of drug infusion and  
no return of seizure activity  
during next 12 h
vPA effective in 88%, PHT  
in 84%.
class iii. 30% of patients  
were , 18 years old
Abbreviations: N, number of participants; iv, intravenous; BDZ, benzodiazepine; SE, status epilepticus; NcSE, nonconvulsive status epilepticus; GcSE, generalized convulsive 
status epilepticus; PHT, phenytoin; PHB, Phenobarbital; vPA, valproic acid. 
The practice
Potential pitfalls
Potential pitfalls include failure to recognize and treat 
the underlying cause of the seizure, failure to recognize 
associated injuries or complications such as aspiration 
pneumonia, and failure to diagnose and treat nonconvulsive 
status epilepticus. If a patient presents with unexplained 
altered mental status or if the level of consciousness and 
awareness fails to improve within 20 to 30 minutes after 
cessation of generalized seizure activity, one must rule 
out the presence of nonconvulsive status. Neurologic con-
sultation is advised when status epilepticus is refractory 
to standard first- and second-line therapies, when EEG is Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Treatment algorithm for status epilepticus in the elderly
Step 1 (0–5 minutes)
  •  Assess airway, apply oxygen and pulse oximetry
  •  Begin cardiac telemetry and hemodynamic monitoring
  •  venipuncture to secure access with 2 large-gauge intravenous catheters
  •    Stat blood work: basic metabolic panel, liver function tests, calcium, magnesium, phosphate, complete blood count, toxicology screens, troponin, 
arterial blood gas, and antiepileptic drug levels if appropriate
  •  Check finger-stick glucose
  •  Begin normal saline drip
Step 2 (6–10 minutes)
  •  Administer 100 mg thiamine iv
  •  Administer 50 mL of 50% dextrose iv if hypoglycemic, but withhold if normoglycemic
  •  Administer 0.1 mg/kg iv lorazepam (, 2 mg/min)
			o  if seizures persist, may repeat initial dose of lorazepam once
			o  Beware of sedation, respiratory depression, and hypotension
  •  if no iv access, consider rectal diazepam 10–20 mg
			o  if seizures persist, may repeat initial dose of diazepam once
			o  Beware of sedation, respiratory depression, and hypotension
Step 3 (11 to 30 minutes)
  •  Administer 20 mg PE/kg iv fosphenytoin (, 150 mg PE/min) or iv 20 mg/kg phenytoin by slow push (, 50 mg/min)
			o  Fosphenytoin
      Beware of cardiac depression and arrhythmia, hypotension, parasthesias, and pruritis
        Fosphenytoin is more expensive but can be infused at a faster rate, has a lower risk of peripheral infusion-site complications, and is 
compatible with glucose-containing IV fluids
(Continued)
required to rule out nonconvulsive status, and when EEG is 
necessary in circumstances when neuromuscular blockade 
is initiated.
Management
Any seizure lasting more than 5 minutes warrants intervention 
because the longer a seizure propagates, the more difficult 
termination will become. The goal of treatment is to stop 
all clinical and electrographic seizure activity. If intubation 
is required for airway protection, prolonged neuromuscular 
blockade should be avoided so as not to confound the neu-
rologic exam if possible. If neuromuscular blockade is used, 
EEG monitoring may be necessary to detect electrographic 
seizures.
Determining the etiology of the seizures will often guide 
further diagnostics and management. Acutely, a head CT is 
recommended to investigate for intracranial pathology once 
the seizures are under control. Further imaging such as brain 
MRI may be warranted if the CT is unrevealing. If infection 
is suspected as the etiology, empiric antibiotic and antiviral 
treatment should not be delayed and further diagnostics such 
as lumbar puncture should be pursued once the seizures are 
aborted.8
Assessment
Important inquiries to make about the patient’s history 
include prior seizures or diagnosis of epilepsy, antiepileptic 
medication compliance, systemic or intracranial malignan-
cies, infections, metabolic disorders, toxic ingestions, alcohol 
use, and recent falls or head injuries. The history may pro-
vide clues as to the etiology of the seizure and guide further 
work-up and management.
Physical examination should first and foremost be dedicated 
to the assessment of airway, breathing, and circulation. A survey 
for evidence of trauma with special attention to the head or face 
should be performed. Assessment of level of consciousness 
and close observation of motor and eye movements can help 
determine whether the seizures are convulsive or nonconvulsive 
in nature, simple or complex, and focal or generalized.8
Treatment
Carried out in 5 time specific steps as described in Table 2.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 2 (Continued)
o  Phenytoin
      Beware of cardiac depression and arrhythmia, hypotension, infusion site soft tissue, and vascular injury (“purple-glove syndrome”)
      incompatible with glucose-containing solutions
  •  Monitor respiratory status, cardiac rhythm, and blood pressure and be prepared to adjust dosages and rates accordingly
  •  if seizures persist, give additional iv fosphenytoin or phenytoin to a maximum total dose of 30 mg/kg
Step 4 (31–50 minutes)
  •  if seizures persist, order urgent EEG and neurologic consultation and transfer patient to intensive care unit
  •  initiate intubation before using an anesthetic agent
  •  consider using one of the following:
o  iv phenobarbital 20 mg/kg slow push (, 100 mg/min)
      Then continuous infusion at 1 mg/kg/h to 4 mg/kg/h
      Beware of respiratory and cardiac depression, prolonged sedation, allergy, and blood dyscrasias
      contraindicated in severe liver dysfunction
   o  iv pentobarbital 5 mg/kg (, 50 mg/min)
      Then continuous infusion at 0.5 mg/kg/h to 5 mg/kg/h
      Beware of respiratory depression, sedation, and hypotension
   o  iv midazolam 0.2 mg/kg (given over 20–30 seconds)
      Dose may be repeated in 5 minutes if seizures persist
      Then continuous infusion at 0.05 mg/kg/h to 2.0 mg/kg/h
      Beware of respiratory depression, sedation, and hypotension
o  iv propofol 1 mg/kg bolus
      May give repeated boluses every 3–5 minutes to a maximum dose of 10 mg/kg
        Beware of sedation, hypotension, bradycardia, allergic reaction, and “propofol infusion syndrome” at high doses (metabolic acidosis, 
cardiac failure with dysrhythmia, rhabdomyolysis, hyperkalemia, and lipemia)
      Monitor acid base status
      continuous infusion involves a large lipid and caloric load
  •  Non-sedating alternatives include:
o  iv valproate bolus of 25 mg/kg to 30 mg/kg (, 3 mg/kg/min)
      Not FDA approved for SE
      May be useful in patients who are awake, patients with primary generalized epilepsy, or in situations where intubation is to be avoided
      Beware of dizziness, hyperammonemia, hypotension, hepatotoxicity, thrombocytopenia, and pancreatitis
      contraindicated in severe liver dysfunction, thrombocytopenia, and active bleeding
      Monitor liver profile, amylase, lipase, and complete blood cell count
  o  iv levetiracetam 20 mg/kg over 15 minutes
      Not FDA approved for SE
        May be useful in patients who are awake, patients with primary generalized epilepsy, patients with liver disease, or situations in which 
intubation is to be avoided
      Beware of neuropsychiatric side effects
      Dose must be lowered in those with impaired creatinine clearance
o  iv lacosamide
      Not FDA approved for SE
Step 5
  •    if seizures persist, maintain continuous iv infusion of anesthetic agents and titrate dose to desired level of EEG suppression-burst as determined 
by the neurology consultant
  •  Defer to neurology consultant for choice of maintenance antiepileptic drug and appropriate dosing
Adapted with permission from Waterhouse E. Status epilepticus. Continuum Lifelong Learning Neurol. 2010:16(3):199–227.8
Abbreviations: SE, status epilepticus; PE, phenytoin equivalents. Neuropsychiatric Disease and Treatment
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Further reading
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